Supplemental Figures from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers
Meghan M. Joly(UL Research Institutes), Rebecca S. Cook(Vanderbilt University), Dos D. Sarbassov(Nazarbayev University), Violeta Sánchez(Vanderbilt University), Donna J. Hicks(Vanderbilt University), Bayley A. Jones(University of Alabama at Birmingham), Dana M. Brantley‐Sieders(Susan G. Komen Breast Cancer Foundation), William J. Muller(Lurie Children's Hospital), Michelle D. Williams(The University of Texas MD Anderson Cancer Center), Brent N. Rexer(Vanderbilt University Medical Center), Christian D. Young(Raptamer Discovery Group (United States)), Mónica V. Estrada(Vanderbilt University)
Cited by 0
Related Papers
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling
|Journal of Clinical Investigation|2008|276